ADA: degludec noninferior for cardiovascular events in T2DM

(HealthDay)—Among high-risk patients with type 2 diabetes, degludec is noninferior to glargine in terms of the incidence of cardiovascular events, according to a study published online June 12 in the New England Journal of Medicine. The research was published to coincide with the annual meeting of the American Diabetes Association, held from June 9 to 13 in San Diego.

Steven P. Marso, M.D., from the Research Medical Center in Kansas City, Mo., and colleagues randomized 7,637 patients with type 2 diabetes (85.2 percent with established cardiovascular disease, , or both) to receive either insulin degludec (3,818 patients) or U100 (3,819 patients) once daily between dinner and bedtime.

The researchers found that the primary outcome of first occurrence of an adjudicated major cardiovascular event occurred in 8.5 and 9.3 percent of patients in the degludec and glargine groups, respectively (hazard ratio, 0.91; 95 percent confidence interval, 0.78 to 1.06; P < 0.001 for noninferiority). The mean glycated hemoglobin level was 7.5 ± 1.2 percent in each group at 24 months, while the degludec group had a significantly lower mean fasting plasma glucose level (128 ± 56 versus 136 ± 57 mg/dL; P < 0.001). There was no between-group difference in the rates of adverse events.

"Among patients with type 2 diabetes at high risk for , degludec was noninferior to glargine with respect to the incidence of major cardiovascular events," the authors write.

The study was funded by Novo Nordisk, the manufacturer of degludec.

Explore further

Insulin degludec lowers risk of recurrent low blood sugar or has similar risk to insulin glargine

More information: Abstract
Full Text
More Information
Journal information: New England Journal of Medicine

Copyright © 2017 HealthDay. All rights reserved.

Citation: ADA: degludec noninferior for cardiovascular events in T2DM (2017, June 14) retrieved 1 October 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors